LE WE PMID CA
JAK2V617F8824JAK2V617F

Acquired sideroblastic anemia with unilineage dysplasia WHO RARS

ASXL1

Cbl

Essential thrombocythemia

IDH1 Isocitrate dehydrogenase1 NADP soluble

IKZF1

JAK STAT

Jak2

JAK2V617F

Leukemia (acute myeloic)

Leukemia (chronic myeloic)

Leukemia (chronic myelomonocytic leukaemia)

Mastocytosis

MPLW515L

Myelodysplastic syndrome

Myelofibrosis

Myeloproliferative syndromes

Polycythemia vera

Receptor (Erythropoietin)

Receptor (G CSF)

Receptor (Thrombopoietin)

TET2

Thrombophilia

2009  
1
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.
[19273837] Blood 113(22): 5617-23 (2009)
2011  
2
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.
[21242185] Haematologica 96(4): 590-601 (2011)
2006  
3
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
[17124067] Hematology Am Soc Hematol Educ Program -(-): 240-5 (2006)
2006  
4
Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
[17124066] Hematology Am Soc Hematol Educ Program -(-): 233-9, 510 (2006)
2007  
5
Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.
[18024651] Hematology Am Soc Hematol Educ Program -(-): 355-62 (2007)
2008  
6
The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
[19074061] Hematology Am Soc Hematol Educ Program -(-): 69-75 (2008)
2008  
7
The role of JAK2 mutations in RARS and other MDS.
[19074058] Hematology Am Soc Hematol Educ Program -(-): 52-9 (2008)
2009  
8
2009  
9
Thrombopoietin in normal and neoplastic stem cell development.
[19959099] Best Pract Res Clin Haematol 22(4): 495-9 (2009)
2007  
10
The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.
[17336249] Best Pract Res Clin Haematol 20(1): 5-12 (2007)
2006  
11
JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
[16755940] Ulster Med J 75(2): 112-9 (2006)
2009  
12
Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.
[19216843] Curr Oncol Rep 11(2): 117-24 (2009)
2010  
13
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
[20428194] Leukemia 24(6): 1128-38 (2010)
2010  
14
Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.
[21442038] Genes Cancer 1(10): 979-93 (2010)
2006  
15
JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
[16931578] J Mol Diagn 8(4): 397-411; quiz 526 (2006)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



Search PubMed and many other databases on the combined search terms

GG: JAK2V617F

  • JAK2V617F

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia